Over the last few decades, the integration of chemotherapy and radiation has played a crucial role in the management of locally advanced non-small cell lung cancer (NSCLC). Locally advanced NSCLC is a very heterogeneous disease. Because of this heterogeneity, advanced NSCLC can be managed in various ways depending on the bulk of disease, the comorbidities of the patient, and the expertise and resources of the treating physicians and facilities. This review describes the evolution of current treatment strategies and predicted future changes for the management of locally advanced NSCLC.
L ung cancer is the leading cause of cancer death in the United States among men and women. 1 More than one third of patients newly diagnosed with non-small cell lung cancer (NSCLC) present with locally advanced, typically unresectable disease. Over the last few decades, the integration of chemotherapy and radiation has played a crucial role in the management of locally advanced NSCLC. Locally advanced NSCLC is a very heterogeneous disease. For example, patients with clinically apparent or bulky N2 disease have survival rates ranging from about 3% to 8%. 2Y4 In contrast, patients who are discovered to have pathological N2 disease at the time of surgery have long term-survival rates ranging from 10% to 50%. Because of this heterogeneity, advanced NSCLC can be managed in various ways depending on the bulk of disease, the comorbidities of the patient, and the expertise and resources of the treating physicians and facilities. This review describes the evolution of current treatment strategies and predicted future changes for the management of locally advanced NSCLC.
DEFINITIVE CHEMORADIATION Radiation TherapyYAlone Trials
Prior to the advent of combined modality therapy for unresectable stage III NSCLC, definitive radiation therapy (RT) was the primary therapeutic strategy. Beginning in the 1960s, RT was shown to be superior to supportive care in patients with locally advanced NSCLC. 5 A multi-institutional Veterans Affairs study compared RT alone (40Y50 Gy) to supportive care among patients with both small cell lung cancer (SCLC) and NSCLC. Despite numerous limitations such as the inclusion of SCLC, inadequate staging, and antiquated RT techniques, this trial demonstrated a statistically significant survival advantage at 1 year among patients randomized to the RT arm (18.2% vs 13.9%; P = 0.05). More recent studies have determined that definitive RT for locally advanced, unresectable NSCLC is associated with an approximate 10-month median survival and a 5-year survival rate of about 5%. 5Y7 The current standard dose of radiation was established in a historic phase III Radiation Therapy Oncology Group (RTOG) trial, which compared various doses and treatment durations of RT for medically inoperable NSCLC. 8 In this study, 376 patients were randomized to 40 Gy (split course), 40 Gy (continuous course), 50 Gy, and 60 Gy in 2-Gy fractions. Those who received 60 Gy demonstrated an improvement in intrathoracic tumor control rates compared with lower doses (67% vs 58% vs 56% vs 48%; P = 0.02). Furthermore, complete response rates were significantly higher in the groups receiving 50 or 60 Gy (23%Y24%; P = 0.04). Importantly, this study also showed that tumor response based on chest radiographs and intrathoracic tumor control directly correlated with survival. Patients who received 50 and 60 Gy and who were alive at 12 months with local tumor control had a median survival of 23 months in contrast to a median survival 12 months if they had local failure before 12 months (P = 0.05). Those who received 40 Gy had a median survival of 17 months if local control was achieved in the first 12 months, and 12-month median survival if there was local failure by 12 months, respectively (P = 0.008).
Multiple RT dose-escalation studies have been performed to evaluate RT doses more than 60 Gy. 9Y11 A phase I doseescalation study enrolled 104 patients with inoperable stage IYIII NSCLC to receive 3-dimensional conformal RT (CRT). 12 This study determined the maximum tolerated dose (MTD) of 3-dimensional CRT to be 84 Gy.
Another study for patients with stage IYIII NSCLC treated 18 patients to doses of 92.4 or 102.9 Gy. 13 Both trials permitted neoadjuvant chemotherapy. This study demonstrated that patients with low-volume disease could be safely treated to 92.4 or 102.9 Gy with minimal toxicity. The majority of RT doseescalation trials were modified to chemoradiotherapy designs once this became a de facto standard.
RT Dose Escalation With Chemotherapy
With the evolution of combined modality approaches for the management of locally advanced NSCLC, several studies have sought to investigate the safety of dose escalation of RT with concurrent chemotherapy. A phase I study determined the maximum tolerated dose of radiation to be 74 Gy given with concurrent weekly carboplatin and paclitaxel. 10 Another dose-escalation study treated patients with induction carboplatin, irinotecan, and paclitaxel followed by concurrent carboplatin and paclitaxel with CRT, achieving doses of 78 to 90 Gy with relatively low toxicities. 14 The Cancer and Leukemia Group B (CALGB) 30105 phase II trial of induction chemotherapy randomized 69 patients to arm A (induction carboplatin and paclitaxel followed by concurrent weekly carboplatin and paclitaxel and RT to 74 Gy) or arm B (induction carboplatin with gemcitabine, followed by concurrent gemcitabine and RT to 74 Gy). 11 Arm B was closed early because of a high rate of grades 4 and 5 pulmonary toxicity. Compared with historical controls, the median survival of 24.3 months in arm A was very encouraging.
Radiation Therapy Oncology Group 0117 treated 55 patients with carboplatin and paclitaxel with 74 Gy of concurrent RT. 9 The median survival for all patients was 25.9 months. Furthermore, the toxicity profile was favorable, but 2 grade 5 acute toxicities occurred, with 1 grade 5 pneumonia and 1 grade 5 hemoptysis. These encouraging median survival times of 21 to 37 months paved the way to studying higher doses of RT in the phase III setting.
More recent phase III studies have attempted to evaluate if higher doses conferred advantages to the standard 60 Gy. 15, 16 A study of involved-field irradiation (IFI) versus elective nodal irradiation (ENI) randomized 200 patients to receive concurrent cisplatin-based chemotherapy with either IFI at 68 to 74 Gy or ENI at 60 to 64 Gy. 15 This study demonstrated that patients who received IFI with concurrent chemotherapy had better 5-year local control rates compared with those who received ENI (51% vs 36%; P = 0.032). Importantly, radiation pneumonitis rates were also lower among patients who received INI compared with ENI (17 vs 29%; P = 0.044).
Radiation Therapy Oncology Group 0617 is a multiinstitutional 4-arm trial comparing carboplatin plus paclitaxel with or without cetuximab, assigning patients to receive either 60 or 74 Gy of concurrent RT. 16 Interim results have been presented in abstract form only. The higher-dose radiation arms of the study were terminated early after futility analysis did not demonstrate any advantage to 74 Gy. In fact, at interim analysis, there was a significantly inferior survival rate for the high-dose RT arm (hazard ratio [HR], 1.45; 95% confidence interval [95% CI], 1.05Y2.05; P = 0.02), speculatively due to increased toxicities, although the principal investigator is currently reviewing these events in greater detail. The standard-dose arms of chemotherapy with or without cetuximab remained open, and results are pending.
These negative trials all pursued dose escalation without reducing overall treatment time. It has been well established that NSCLC is a rapidly proliferating neoplasm, with a rather short time to accelerating its proliferative response to the initiation of RT. One approach at overcoming this is through schedule shortening, either through aggressive accelerated hyperfractionation or dose-per-fraction intensification. In the phase III randomized UK trial, 536 patients were randomized to CHART (continuous hyperfractionated accelerated RT) 1.5 Gy thrice daily for 15 consecutive days to a total dose of 57 Gy versus 60 Gy in 30 fractions, without concurrent chemotherapy. 17 There was an improvement in 2-year overall survival (OS) of 29 versus 20% (P = 0.004) for CHART versus standard fractionation. The benefit was even more pronounced in squamous cell histologies (33 vs 20%; P = 0.0007). Furthermore, there was a reduction in local control, regional failure, and distant failure with CHART.
This concept of accelerated hyperfractionation was further corroborated through Eastern Cooperative Oncology Group (ECOG) 2597 randomized trial of standard radiation versus accelerated hyperfractionation after induction chemotherapy, a phase III trial where 119 patients received induction carboplatin and paclitaxel for 2 cycles followed by either standard radiation to 64 Gy at 2 Gy per fraction versus hyperfractionated accelerated RT (thrice daily for 12 treatment days) to a dose of 57.6 Gy. 18 The study showed a trend toward improved OS with hyperfractionated accelerated RT (20.3 vs 14.9 months). Although underpowered, the results are intriguing. Mehta and colleagues 19 described a new concept of dose escalation in NSCLC. Given that NSCLC repopulation is rapid, and the cell doubling time is less than 4 days, they proposed a dose-per-fraction escalation strategy that maintained the number of fractions at 25 treatments, but increased the dose per fraction to help maintain the same risk of pneumonitis, while increasing the local control. 19 This model was later tested clinically in a phase I dose-escalation model with the first 46 patients treated reported by Adkison and colleagues. 20 In this study, patients were placed in 1 of 5 dose bins to 25 fractions with doses ranging from 2.28 to 3.22 Gy per fraction. Normalized tissue dose (NTD) equivalents were between 60 and 100 Gy (with absolute noncorrected doses ranging from 57 to 80.5 Gy). No concomitant chemotherapy was delivered, but pre-or post-RT chemotherapy was permitted. Initial toxicity results showed no evidence of grade 3 acute pneumonitis or esophagitis. Early median survival was a promising 18 months with 2-year OS of 46.8%. Longer-term data are pending.
Therefore, despite encouraging phases I and II results for dose escalation of RT, this has yet to be confirmed in the phase III setting, and thus, 60 Gy remains the standard RT dose for concurrent chemoradiotherapy for locally advanced NSCLC.
Sequential Chemoradiotherapy
A pivotal trial that introduced the use of chemotherapy with RT as a standard of care in locally advanced NSCLC was the CALGB 8433 trial. 21 One hundred fifty-five patients with stage III NSCLC were randomized to vinblastine weekly for 5 weeks, and cisplatin on days 1 and 29 followed by 60 Gy of RT or to 60 Gy alone. The median survival for the sequential arm was 13.8 months compared with 9.7 months for the RTalone arm (P = 0.0066). In addition, the 1-, 2-, and 3-year survival rates in the sequential chemoradiotherapy group were 55%, 26%, and 23%, respectively, compared with 40%, 13%, and 11% in the RT-alone arm. A 7-year update of this trial confirmed durable survival advantage for sequential chemoradiotherapy (P = 0.012). 6 Survival rates for chemoradiotherapy at 5 and 7 years were 17% and 13%, respectively, compared with 6% and 6% in the RT-alone arm.
Another RTOG trial evaluated the addition of chemotherapy to RT and also evaluated hyperfractionated RT as a method to dose escalate with similar late adverse effects. 7, 22 This trial confirmed the results of the CALGB trial demonstrating that induction chemotherapy followed by standard-dose RT resulted in a survival advantage compared with RT alone with a median survival of 13.2 months and 5-year survival of 8% compared with a median survival of 11.4 months and a 5-year survival of 5% in the standard-dose RT arm (P = 0.04).
The NSCLC Collaborative Group performed a metaanalysis to evaluate the role of chemotherapy with RT using individual patient data on 9387 patients from 52 randomized trials. 23 Twenty-two trials included 3033 patients who evaluated RT versus RT in addition to various chemotherapy regimens. Overall, the addition of chemotherapy to RT for locally advanced disease conferred a survival advantage (HR, 0.90; P = 0.006), and surprisingly, this benefit was almost solely from a reduction in local relapse without a significant impact on distant metastatic disease. In addition, there was a survival advantage for cisplatin-based chemotherapy (compared with noncisplatin regimens), with HR of 0.87 (P = 0.005). The results of this meta-analysis, along with the 2 primary phase III trials, set the standard that sequential chemoradiotherapy is superior to RT alone for locally advanced, surgically unresectable NSCLC.
Concomitant Chemoradiotherapy
Multiple phase III studies have demonstrated an advantage of concurrent chemoradiotherapy over sequential chemoradiation, and this is currently the standard of care ( Table 1 ). The West Japan Lung Cancer Group performed a phase III trial with 320 patients comparing concurrent cisplatin, vindesine, and mitomycin with a planned split course of radiation to a total of 56 Gy, versus the same chemotherapy delivered sequentially before continuous course of 56 Gy of radiation. 24 Concurrent therapy conferred a survival advantage over sequential therapy with a median survival of 16.5 versus 13.3 months (P = 0.04) and 5-year survival of 17.9% versus 7.1%, respectively.
The RTOG 9410 trial involving 610 patients also demonstrated a survival advantage for concurrent over sequential chemoradiation. 25 Patients were assigned to 1 of 3 treatment arms. Arm 1 received sequential cisplatin and vinblastine for 5 weeks followed by 63 Gy (n = 203), arm 2 received concurrent cisplatin and vinblastine with 63 Gy (n = 204), and arm 3 received concurrent cisplatin and oral etoposide with hyperfractionated RT to 69.6 Gy (n = 203). Five-year survival rates were significantly higher for arm 2 compared with arm 1 (HR for death, 0.812; 95% CI, 0.663Y0.996; P = 0.046), but not for arm 3 versus arm 2 (HR for death, 0.925; 95% CI, 0.752Y1.138; P = 0.46). The lack of benefit from arm 3 may have been related to the regimen being too toxic leading to treatment breaks. The rates of grade 3 and higher esophagitis were 4%, 22%, and 45% for arms 1 to 3, respectively (P G 0.001) ( Table 2 ). Based on these results, concurrent chemoradiotherapy has become the standard therapy for fit patients with locally advanced, unresectable lung cancer. Two recent meta-analyses redemonstrated an advantage to concurrent chemoradiotherapy over sequential chemoradiotherapy. 26, 27 In an updated Cochrane meta-analysis, 5 clinical trials, which included 937 participants, showed a significant benefit in OS (HR, 0.74; 95% CI, 0.62Y0.89) and in 2-year survival (relative risk [RR], 0.87; 95% CI, 0.78Y0.97) for those receiving concurrent versus sequential chemoradiotherapy. This translated into an absolute 2-year survival advantage of 10%.
A second meta-analysis was performed by the NSCLC Collaborative Group, which included 6 trials and individual patient data for 1205 patients who were randomized to concomitant versus sequential chemoradiotherapy. This meta-analysis demonstrated a similar advantage for OS for patients receiving concomitant over sequential therapy (HR, 0.84; 95% CI, 0.74Y0.95; P = 0.004). The analysis also showed a benefit for concurrent chemoradiotherapy in terms of locoregional progression (HR, 0.77; CI, 0.62Y0.95; P = 0.01) but not for distant progression (HR, 1.04; 95% CI, 0.86Y1.25; P = 0.69). These data suggest that the survival advantage for concurrent chemoradiotherapy results from the improved locoregional control achieved with concurrent chemoradiotherapy.
Despite improvements in locoregional control, rates of distant metastatic failures in patients who receive either concurrent or sequential chemoradiotherapy are similar at around 35% to 40%. 25, 28 Unfortunately, phase III studies to evaluate the role of induction chemotherapy or consolidation chemotherapy after concurrent chemoradiotherapy have not demonstrated improvements by the addition of induction or consolidation chemotherapy. 29, 30 This paves the way for future studies to work toward improving locoregional control in locally advanced NSCLC and to also address death due to distant metastatic disease.
Toxicity of Chemoradiotherapy
Compared with RT alone, concurrent chemoradiotherapy is associated with higher rates of treatment-related morbidity. 27 In a systematic review, treatment-related morbidity and mortality were evaluated for 19 randomized studies where patients received either concurrent chemoradiotherapy or RT alone. There was a numerically higher rate of treatment-related deaths in the concurrent chemoradiotherapy arm compared with RT alone (RR, 1.38; 95% CI, 0.51Y3.72), but this is not statistically significant. There were, however, statistically significant higher rates of acute grade 3 or worse esophagitis (RR, 1.76; 95% CI, 1.34Y2.31), neutropenia (RR, 3.53; 95% CI, 1.84Y6.77), and anemia (RR, 4.17; 95% CI, 1.13Y15.35) for concurrent chemoradiotherapy compared with RT alone.
This systematic review also compared treatment-related morbidity and mortality for concurrent versus sequential chemoradiotherapy. 27 Again, there were numerically (4% vs 2%) higher rates of treatment-related mortality for the concurrent versus sequential chemoradiotherapy groups, but this was not statistically significant (RR, 2.02; 95% CI, 0.90Y4.52). There were also higher rates of grade 3 or higher esophagitis in the concurrent group (RR, 4.96; 95% CI, 2.17Y11.37). There were no significant differences in hematologic toxicity between those receiving concurrent versus sequential chemoradiotherapy.
Preoperative Chemoradiotherapy
Because many patients experience locoregional failure with current approaches, trimodality therapy with neoadjuvant chemoradiation followed by surgery has been investigated. Multiple phase II studies have suggested a survival advantage for the addition of surgery to induction chemotherapy or chemoradiotherapy. 31Y34 In a phase III study of 524 patients, the surgical arm received 3 cycles of cisplatin and etoposide followed by concurrent chemoradiotherapy using carboplatin, vindesine, and hyperfractionated RT, followed by surgery. 35 Patients who had a positive margin at the time of surgery were offered adjuvant RT. The control group was given 3 cycles of cisplatin and etoposide followed by surgery and then RT. Although there was a significant improvement in mediastinal down-staging and pathological response in the intervention group, there was no significant difference in median progression-free survival (PFS) (9.5 vs 10 months; P = 0.87) or OS (median OS 15.7 vs 17.6 months; P = 0.97).
The Intergroup 0139 phase III trial randomized patients to 1 of 2 groups. 36 Group 1 (n = 202) received cisplatin and etoposide concurrently with 45 Gy of RT followed by surgical resection for patients who did not have progressive disease. Group 2 (n = 194) received cisplatin and etoposide concurrently with RT (61 Gy) without surgical resection. Although PFS was improved for group 1 versus group 2 (12.8 vs 10.5 months; P = 0.017), there was no difference in OS between groups 1 . Based on an unplanned subset analysis, patients who received a lobectomy after chemoradiotherapy, OS was superior compared with the chemoradiotherapy-alone group (median survival, 33.6 vs 21.7 months; P = 0.002). Based on these results, trimodality therapy for locally advanced NSCLC remains controversial but can be considered by centers with experience in this treatment approach for selected patients, especially with the clear desire to avoid pneumonectomy. Radiation Therapy Oncology Group 0229 and the currently accruing RTOG 0839 have demonstrated low mortality rates for experienced surgeons after full-dose chemoradiation. This approach appears to increase the pN0 rate in the multi-institutional setting, although it has not been tested in the phase III setting.
Adjuvant Radiation Therapy or Chemoradiotherapy
Recent clinical trials using adjuvant platinum-based chemotherapy have shown significant improvements in survival for patients with resected NSCLC, and the majority of the benefit appears to be in resected stages II and III NSCLC. The Lung Adjuvant Cisplatin Evaluation meta-analysis evaluated individual patient data from the largest clinical trials of adjuvant chemotherapy and included 4584 patients, showing a significant improvement in survival with the addition of chemotherapy for stage II (HR, 0.83; 95% CI, 0.73Y0.95) and stage III (HR, 0.83; 95% CI, 0.72Y0.94). 37 For patients with stage IB resected lung NSCLC, there was not a significant improvement in survival (HR, 0.93; 95% CI, 0.78Y1.10). In contrast, the JBR.10 trial randomized 482 patients with resected stage IB or II NSCLC to either surgery alone or surgery with adjuvant vinorelbine plus cisplatin. In an exploratory Cox regression analysis, this study demonstrated a trend toward improved survival in stage IB tumors more than 4 cm (HR, 0.66; 95% CI, 0.39Y1.14; P = 0.13). 38 At present, adjuvant chemotherapy in resected lung cancer has become the mainstay of therapy for resected stage II, stage III, and in some stage IB NSCLC.
Because a significant proportion of patients with NSCLC who underwent surgical resection also experience local failure, adjuvant RT has also been studied to improve locoregional failure rates. In patients who were considered ''high risk'' based on the number of involved lymph nodes and the level of mediastinal lymph node involvement, retrospective studies have suggested there may be a survival advantage for the use of adjuvant RT. 39 Randomized trials, however, have not confirmed these findings. Subsequent meta-analyses were performed to improve the power of detecting significant survival differences in these small clinical trials. The Lung Cancer Study Group published a randomized trial of 210 patients with N1 or N2 disease to observation or postoperative radiation therapy (PORT), which was powered to demonstrate an improvement in localregional control. This study did demonstrate an improvement in local control, although there was no improvement in OS. 40 The PORT meta-analysis identified 9 randomized controlled trials with data from 2128 subjects who had completely resected stage I to IIIA NSCLC. 41 Postoperative radiation doses varied between trials and ranged from 30 to 60 Gy, and the majority of patients had stage II or III NSCLC. This metaanalysis demonstrated that postoperative RT appeared to have a detrimental effect with an HR for death of 1.21 (95% CI, 1.08Y1.34; P = 0.001). Local recurrence-free survival and distant recurrence-free survival also favored the surgery-alone arm. The PORT meta-analysis has been criticized for a number of reasons primarily related to the techniques utilized dating back into the 1960s. The best example of these antiquated techniques is the French trial, which made up 35% of the patient population in the analysis. 42 This trial demonstrated the highest rate of death related to intercurrent disease (35%). This trial used the largest field size including a large part of the heart and lung while additionally delivering the highest dose of RT (60 Gy) and allowed the use of cobalt RT. In addition, this trial also demonstrated a higher intercurrent death rate related to higher doses per fraction. Over the last 2 decades, the use of more conventional total doses, dose per fractions and smaller target volumes, the rates of intercurrent disease, and treatmentrelated morbidity have decreased substantially. 43Y45 An analysis of the Surveillance, Epidemiology, and End Results database was performed on patients with stage II or III NSCLC who underwent a lobectomy or pneumonectomy between 1988 and 2002. 46 The purpose of this analysis was to explore if more modern treatment methods of RT had a positive impact as opposed to those observed in the PORT metaanalysis; 7465 patients who received PORT or observation after surgical resection were included. In contrast to the PORT meta-analysis, multivariate analysis of the Surveillance, Epidemiology, and End Results did not demonstrate a significant impact on OS by the use of PORT (HR, 1.048; 95% CI, 0.987Y1.113; P = 0.1269). This lack of detriment may be a result of less heart diseaseYrelated deaths. 47 However, on a subset analysis, there was a significant detriment to survival in patients with N0 (HR, 1.1176; 95% CI, 1.005Y1.376; P = 0.0435) or N1 (HR, 1.097; 95% CI, 1.015Y1.186; P = 0.0196) disease. Interestingly, this analysis did show a significant improvement in survival for patients who had N2 nodal disease and received PORT RT after surgery (HR, 0.855; 95% CI, 0.762Y0.959; P = 0.0077). Questions remain regarding the use of PORT following surgery, particularly in the era of adjuvant chemotherapy, but N2 patients should be considered for PORT.
The question becomes whether improvements in local control can improve survival in the postoperative setting when chemotherapy is increasing survival presumably by decreasing distant metastatic disease. In a German phase II trial using induction docetaxel and cisplatin before surgery for pathological N2 disease, 45 of 75 patients went on to develop local-regional failure, suggesting chemotherapy alone is inadequate for local control in this setting. 48 In a retrospective analysis of patients treated on the ANITA (Adjuvant Navelbine International Trialist Association) trial, Douillard et al 49, 50 demonstrated that the addition of PORT following chemotherapy improved the 5-year survival from 34% to 47% for patients with N2 disease. The use of PORT on this trial was not randomized but was allowed based on institution preference. PORT was delivered in a sequential fashion following chemotherapy on this trial. The CALGB tried to conduct a phase III for patients with N2 disease where patients received 4 cycles of carboplatin and paclitaxel and were then randomized to receive PORT or observation. This trial closed early in 2000 because of poor accrual, although based on the 40 patients who were accrued, the median failure-free survival favored those who received PORT (25.9 vs 15.6 months). Currently, the French are accruing to a phase III study led by Le Pechoux called Lung ART (Lung Adjuvant Radiotherapy Trial). In the United States, the National Comprehensive Cancer Network guidelines suggest PORT for those with N2 disease found at the time of surgery. 51 
FUTURE DIRECTIONS
Future directions for the management of locally advanced NSCLC include the incorporation of newer technology, improved RT techniques, minimization of toxicity, decreasing the risk of distant metastatic disease, and more individualized therapies such as histology-based approaches and therapies guided toward newly discovered molecular targets.
Positron Emission Tomography Scan
Positron emission tomography (PET) has led to more accurate staging of NSCLC. Its sensitivity and specificity to detect distant metastatic disease are significantly higher than those of computed tomography (CT) in NSCLC. 52 Positron emission tomography imaging may also have value as a therapeutic planning and selection tool in the management of locally advanced NSCLC. Positron emission tomography scans may have an important role in aiding RT planning. Positron emission tomography has been shown to decrease variability between radiation oncologists in planning tumor contours and target volumes. 53, 54 The role of fluorodeoxyglucose (FDG)YPET for radiation planning for clinical stage III NSCLC was evaluated in 1 study, where it was hypothesized that the incorporation of PET could decrease the radiation doses to surrounding normal organs. 55 Twenty-one consecutive patients with clinical stage N2 M0 or N3 M0 NSCLC and SCLC underwent CT scan and PET-CT scan, and RT treatment plans were generated. Nodal tumor volumes were lower in PET-CT planning compared with CT planning (9.9 T 4.0 vs 13.7 T 3.8 cm 3 ; P = 0.011). In addition, doses of radiation could be safely increased from 56.0 T 5.4 Gy with CT planning to 71.0 T 13.7 Gy with PET-CT planning, without increased modeled toxicity to the lung, esophagus, and spinal cord (P = 0.038).
In some novel clinical trials, boosting of residual PETavid disease detected in the middle of chemoradiotherapy is being pursued to increase dose to potentially treatment-resistant disease; novel tracers to dose escalate treatment to hypoxic and/ or hyperproliferative portions of the tumor are also being evaluated. 56, 57 Radiation Therapy Oncology Group 1106/American College of Radiology Imaging Network 6607 trial is a randomized phase II study that plans to enroll 138 patients and evaluates an adaptive approach to RT based on a midtreatment FDG-PET scan. 58 The control arm will have a midtreatment FDG-PET scan, but the RT will stay the same based on the original plan before initiation of treatment. In addition, a baseline PET scan will be obtained in all subjects using a novel radiotracer ( 18 F) fluoromisonidazole to measure hypoxia and to correlate this with outcomes.
TARGETED THERAPIES WITH RADIATION

Histology-Based Approaches
In advanced and metastatic NSCLC, it has become more evident in the last decade that histology plays a crucial role and that therapies are often guided by the histology. For example, in a phase III study comparing cisplatin plus pemetrexed compared with cisplatin plus gemcitabine for advanced NSCLC, a preplanned analysis by histology demonstrated improved efficacy of cisplatin plus pemetrexed over cisplatin plus gemcitabine for nonsquamous histologies. 59 Conversely, there appeared to be improved efficacy of cisplatin plus gemcitabine for squamous cell NSCLC. There are also significant data that sensitivity to pemetrexed may be inversely related to the thymidylate synthase activity in a tumor. 60, 61 The increased expression of thymidylate synthase in squamous cell carcinomas relative to adenocarcinomas may partially explain the variation in response to pemetrexed by histology. As a result, newer studies for locally advanced surgically unresectable NSCLC have started to investigate therapies based on histology.
One large ongoing trial is the PROCLAIM trial, a phase III study of pemetrexed, cisplatin, and RT followed by consolidation pemetrexed versus etoposide, cisplatin, and RT (66 Gy) followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III NSCLC other than predominantly squamous cell histology. 62 Six hundred patients with locally advanced NSCLC and an ECOG performance status 0Y1 will be randomized between the 2 arms.
Epidermal Growth Factor Receptor
The discovery of molecular targets, such as the epidermal growth factor receptor (EGFR) or EGFR mutations, has been crucial for the development of more ''targeted'' and ''individualized'' therapies for patients with NSCLC. In the advanced or metastatic NSCLC setting, molecularly targeted strategies are encouraging, and investigators are starting to test targeted therapies in earlier stages of the disease.
Cetuximab
Although specific kinase-domainYactivating mutations are relatively uncommon, EGFR overexpression, using the H score, is observed in numerous NSCLCs and its activation leading to signal transduction and cell proliferation and has been identified as a poor prognostic factor. 63 In addition, RT can lead to increased EGFR expression, and inhibiting EGFR signaling has been shown to enhance radiation effects. 64, 65 Cetuximab, a monoclonal antibody to EGFR, has been shown to improve OS (HR, 0.74; P = 0.03) and PFS (HR, 0.70; P = 0.006) for patients with locally advanced head and neck cancer compared with RT alone. 66 The FLEX (First-Line Erbitux in Lung Cancer) trial randomized 1125 patients with EGFR-expressing advanced tumors to cisplatin, vinorelbine, and cetuximab versus cisplatin and vinorelbine and demonstrated a modest improvement in survival for the cetuximab arm (HR, 0.871; 95% CI, 0.762Y0.996; P = 0.044). 67 Cetuximab was therefore combined with concurrent chemoradiotherapy. 68 Radiation Therapy Oncology Group 0324 enrolled 93 patients to receive concurrent carboplatin, paclitaxel, and cetuximab with RT. This study resulted in a promising median survival of 22.7 months, providing the rationale to study this regimen in the phase III 16, 69 RTOG 0617 trial, a 4-arm study comparing standard versus high-dose RT and with or without cetuximab, on a standard chemotherapy platform. The cetuximab results are pending.
Erlotinib and Gefitinib
In the past 5 years, the discovery of EGFR-activating mutations has been revolutionary to better understanding NSCLC. Activating mutations in the tyrosine kinase domain of the EGFR receptor predict response to erlotinib and gefitinib, the 2 orally available tyrosine kinase inhibitors of EGFR that have conferred survival benefit in the second-and third-line management of advanced NSCLC. 70Y73 These 2 agents have also demonstrated activity as in vitro radiation sensitizers in NSCLC cell lines. 74, 75 Phases I and II studies combining erlotinib or gefitinib with chemoradiotherapy have been performed and have had varying results and median OS rates ranging between 13 and 26 months. 76, 77 However, in these studies, patients were not selected by clinical or molecular criteria such as EGFR expression or EGFR mutational analysis.
The role of tyrosine kinase inhibitors in locally advanced disease is also controversial, particularly after the results of Southwest Oncology Group S0023 (SWOG S0023) were reported. 78, 79 This was a phase III clinical trial with a planned accrual of 840 patients who had unresectable stage IIIA or IIIB NSCLC. All patients were to receive concurrent cisplatin and etoposide with concurrent radiation to the thorax, followed by 3 cycles of consolidative docetaxel, and then randomized to gefitinib or placebo daily until disease progression, toxicity, or death. However, this trial was closed prematurely after an unplanned interim analysis demonstrated statistically significantly worse outcomes for patients who were randomized to the gefitinib arm. There was a trend toward an inferior median PFS for patients who received gefitinib versus placebo, 8.3 versus 11.7 months (P = 0.17). An even more concerning finding was the inferior median survival for patients who received gefitinib compared with placebo (23 and 35 months, respectively; P = 0.013). These results in a patient population that is not selected for histology or EGFR mutation status are concerning, and future studies in this setting, even in a population enriched for EGFR mutated tumors, should proceed with caution.
There are still limited data on the role of erlotinib or gefitinib in locally advanced NSCLC in patients who have an EGFR mutation or are selected by molecular criteria. One retrospective analysis hypothesized that EGFR mutations may confer sensitivity to RT because lower rates of local relapse were observed in patients with an EGFR mutation versus EGFR wild type (17.8% vs 41.7%; P = 0.005). 80 Furthermore, in the setting of advanced NSCLC, other molecular targets such as the EML4-ALK translocation have been discovered, which is predictive of response to an oral small-molecule inhibitor of the ALK tyrosine kinase, crizotinib. 81 There are in fact 2 proposed prospective trials through RTOG and the Alliance for Clinical Trials cooperative group that will randomize patients with either an EGFR mutation or an EML4-ALK translocation to upfront erlotinib or crizotinib, respectively, followed by concurrent chemoradiotherapy. 82 The control arm in each study will treat patients with standard chemoradiotherapy alone. Other molecular mutations such as ROS1, RET, and KRAS are also the focus of ongoing clinical investigation using targeted therapies. 83, 84 The BATTLE (Biomarker-Integrated Approaches of Targeted therapy for Lung Cancer Elimination) trial was an innovative study for pretreated patients with advanced NSCLC. 85 It was the first study to randomize 255 patients based on biopsymandated biomarker results to erlotinib, sorafenib, vandetanib, or erlotinib plus bexarotene based on real-time biomarker analyses. This study's most notable accomplishment was to demonstrate the feasibility of a more personalized approach to treating lung cancer and performing clinical trials using molecularly based stratification and randomization. Targeting driver mutations such as EGFR mutations or EML4-ALK translocations or adapting therapy based on molecular targets is a promising and feasible approach to personalize therapy in advanced NSCLC, and the treatment of locally advanced NSCLC may similarly evolve.
CONCLUSIONS
Lung cancer remains the most common cause of cancer death in the United States, and many patients present with locally advanced disease. Current and future studies focus on improving local and distant failures for patients using combined modality approaches, improved systemic agents, and individualizing therapeutics with an emphasis on molecular genotyping. Although combined modality therapies have resulted in improved survival for patients presenting with locally advanced disease, outcomes still remain poor, and there is tremendous potential for improvement.
